Bio-Rad Laboratories (NYSE:BIO.B) Stock Price Up 3.6% – Time to Buy?

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO.B) shot up 3.6% during trading on Tuesday . The stock traded as high as $278.30 and last traded at $278.25. 152 shares changed hands during mid-day trading, an increase of 418% from the average session volume of 29 shares. The stock had previously closed at $268.55.

Bio-Rad Laboratories Trading Up 3.6%

The firm’s fifty day simple moving average is $280.24 and its 200 day simple moving average is $294.64. The stock has a market capitalization of $7.51 billion, a P/E ratio of 9.97 and a beta of 1.02. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.19 and a current ratio of 5.62.

Bio-Rad Laboratories (NYSE:BIO.B) last posted its quarterly earnings results on Thursday, February 12th. The company reported $2.51 EPS for the quarter. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The company had revenue of $693.20 million during the quarter.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.